President Trump is weighing the dismissal of the FDA commissioner, a move that would add another high‑profile exit to Health Secretary Robert F. Kennedy Jr.'s tenure. The regulator has been embroiled in disputes over vaping, abortion drugs and broader policy direction, amplifying political pressure ahead of upcoming elections.

The potential ouster follows a period of intense scrutiny, with the former Johns Hopkins surgeon-turned‑surrogate facing criticism from both Congress and industry groups. White House officials praised the administration’s “historic victories,” while the commissioner, Makary, has not responded to comment requests. A decision could shift the agency’s regulatory stance at a volatile time for pharmaceutical and food safety markets.

Separately, Apple and Intel disclosed a collaborative chip effort, though details on which devices will receive the new silicon remain vague. The partnership builds on a $9 billion grant conversion that gave the U.S. government a 10% stake in Intel, a transaction that facilitated Apple’s entry into the talks. Neither company offered further comment, leaving investors to speculate on supply‑chain impacts.

Congressional Republicans celebrated a 4‑3 court ruling that invalidated Virginia’s redistricting map, a win that preserves their slim House majority. The decision underscores the broader partisan scramble over electoral maps, a factor that could influence future regulatory appointments, including the FDA chairmanship.